Psyence Biomedical Ltd - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
PBM Nasdaq 2834

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Psyence Biomedical Ltd

Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR) - Apr 17th, 2024 12:00 pm
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial - Apr 16th, 2024 3:01 pm
Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial - Apr 8th, 2024 12:00 pm
Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business - Mar 26th, 2024 3:06 pm
Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin - Mar 18th, 2024 8:05 pm
Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares - Mar 15th, 2024 8:30 pm
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study - Mar 12th, 2024 3:15 pm
Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones - Mar 12th, 2024 11:00 am
Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division - Mar 11th, 2024 11:00 am
Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study - Mar 6th, 2024 12:00 pm